
Suven Life Sciences to Present Alzheimer's Drug Data at CTAD Conference
Suven Life Sciences announced it will present data on two investigational drug candidates, Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107), at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, USA. The presentations will cover the "Masupirdine Phase-3 Baseline Demographic & Clinical Characteristics" and "Tenaclidine Phase-1 First-In-Human Safety, Tolerability, Pharmacokinetics." The Masupirdine presentation will detail baseline characteristics of patients in the global Phase-3 study for agitation in Alzheimer's patients, with topline results expected in Q2-2027. The Tenaclidine presentation will cover outcomes from Phase-1 studies in healthy subjects. The company highlighted progress in developing therapies for CNS disorders, including Alzheimer's disease.
Key Highlights
- Suven Life Sciences to present Phase-3 Masupirdine and Phase-1 Tenaclidine data.
- Presentations at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.
- Masupirdine topline results for agitation in Alzheimer's patients expected Q2-2027.
- Tenaclidine Phase-1 safety, tolerability, and pharmacokinetic data to be shared.
- Focus on developing innovative therapies for central nervous system (CNS) disorders.
Price Impact
More from SUVEN